These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28446908)

  • 1. Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.
    Queirolo P; Dozin B; Morabito A; Banelli B; Piccioli P; Fava C; Leo C; Carosio R; Laurent S; Fontana V; Ferrucci PF; Martinoli C; Cocorocchio E; Battaglia A; Ascierto PA; Capone M; Simeone E; De Galitiis F; Pagani E; Antonini Cappellini GC; Marchetti P; Guida M; Tommasi S; Mandalà M; Merelli B; Quaglino P; Fava P; Guidoboni M; Romani M; Spagnolo F; Pistillo MP
    Front Immunol; 2017; 8():386. PubMed ID: 28446908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel multiplex pyrosequencing assay for genotyping functionally relevant CTLA-4 polymorphisms: potential applications in autoimmunity and cancer.
    Banelli B; Morabito A; Laurent S; Piccioli P; Dozin B; Ghio M; Ascierto PA; Monteghirfo S; Marasco A; Ottaviano V; Queirolo P; Romani M; Pistillo MP
    Hum Immunol; 2014 Aug; 75(8):730-9. PubMed ID: 24801647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study.
    Queirolo P; Morabito A; Laurent S; Lastraioli S; Piccioli P; Ascierto PA; Gentilcore G; Serra M; Marasco A; Tornari E; Dozin B; Pistillo MP
    Cancer Invest; 2013 Jun; 31(5):336-45. PubMed ID: 23641913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study.
    Pistillo MP; Fontana V; Morabito A; Dozin B; Laurent S; Carosio R; Banelli B; Ferrero F; Spano L; Tanda E; Ferrucci PF; Martinoli C; Cocorocchio E; Guida M; Tommasi S; De Galitiis F; Pagani E; Antonini Cappellini GC; Marchetti P; Quaglino P; Fava P; Osella-Abate S; Ascierto PA; Capone M; Simeone E; Romani M; Spagnolo F; Queirolo P;
    Cancer Immunol Immunother; 2019 Jan; 68(1):97-107. PubMed ID: 30311027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.
    de Joode K; Mora AR; van Schaik RHN; Zippelius A; van der Veldt A; Gerard CL; Läubli H; Michielin O; von Moos R; Joerger M; Levesque MP; Aeppli S; Mangana J; Mangas C; Trost N; Meyer S; Parvex SL; Mathijssen R; Metaxas Y
    J Immunother; 2024 Jun; 47(5):190-194. PubMed ID: 38318726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The -319C/+49G/CT60G haplotype of CTLA-4 gene confers susceptibility to rheumatoid arthritis in Mexican population.
    Torres-Carrillo N; Ontiveros-Mercado H; Torres-Carrillo NM; Parra-Rojas I; Rangel-Villalobos H; Ramírez-Dueñas MG; Gutiérrez-Ureña SR; Valle Y; Muñoz-Valle JF
    Cell Biochem Biophys; 2013; 67(3):1217-28. PubMed ID: 23703660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.
    Queirolo P; Dozin B; Morabito A; Banelli B; Piccioli P; Fava C; Leo C; Carosio R; Laurent S; Fontana V; Ferrucci PF; Martinoli C; Cocorocchio E; Battaglia A; Ascierto PA; Capone M; Simeone E; De Galitiis F; Pagani E; Antonini Cappellini GC; Marchetti P; Guida M; Tommasi S; Mandalà M; Merelli B; Quaglino P; Fava P; Guidoboni M; Romani M; Spagnolo F; Pistillo MP
    Front Immunol; 2018; 9():403. PubMed ID: 29531523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma.
    Wu X; Giobbie-Hurder A; Connolly EM; Li J; Liao X; Severgnini M; Zhou J; Rodig S; Hodi FS
    Oncoimmunology; 2018; 7(7):e1440930. PubMed ID: 29900046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A CT60G>A polymorphism in the CTLA-4 gene of the recipient may confer susceptibility to acute graft versus host disease after allogeneic hematopoietic stem cell transplantation.
    Karabon L; Markiewicz M; Partyka A; Pawlak-Adamska E; Tomkiewicz A; Dzierzak-Mietla M; Kyrcz-Krzemien S; Frydecka I
    Immunogenetics; 2015 Jun; 67(5-6):295-304. PubMed ID: 25940108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of cytotoxic T-lymphocyte antigen-4 polymorphisms on acute rejection onset of cadaveric renal transplants.
    Canossi A; Aureli A; Delreno F; Iesari S; Cervelli C; Clemente K; Famulari A; Pisani F; Papola F
    Transplant Proc; 2013 Sep; 45(7):2645-9. PubMed ID: 24034013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTLA-4, CD28, and ICOS gene polymorphism associations with non-small-cell lung cancer.
    Karabon L; Pawlak E; Tomkiewicz A; Jedynak A; Passowicz-Muszynska E; Zajda K; Jonkisz A; Jankowska R; Krzakowski M; Frydecka I
    Hum Immunol; 2011 Oct; 72(10):947-54. PubMed ID: 21669243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CTLA-4 +49A>G polymorphism of recipients of HLA-matched sibling allogeneic stem cell transplantation is associated with survival and relapse incidence.
    Piccioli P; Balbi G; Serra M; Morabito A; Lamparelli T; Gobbi M; Laurent S; Dozin B; Bruzzi P; Ferraris AM; Bacigalupo A; Notaro R; Pistillo MP
    Ann Hematol; 2010 Jun; 89(6):613-8. PubMed ID: 20020126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma.
    Amin A; Lawson DH; Salama AK; Koon HB; Guthrie T; Thomas SS; O'Day SJ; Shaheen MF; Zhang B; Francis S; Hodi FS
    J Immunother Cancer; 2016; 4():44. PubMed ID: 27532019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves' disease and modulates clinical phenotype of disease.
    Pawlak-Adamska E; Frydecka I; Bolanowski M; Tomkiewicz A; Jonkisz A; Karabon L; Partyka A; Nowak O; Szalinski M; Daroszewski J
    Endocrine; 2017 Jan; 55(1):186-199. PubMed ID: 27638540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure.
    Schreuer MS; Chevolet IL; Jansen YJ; Seremet TC; Wilgenhof S; Liénard D; Del Marmol V; Neyns B
    Melanoma Res; 2015 Feb; 25(1):68-74. PubMed ID: 25396684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab.
    Sade-Feldman M; Kanterman J; Klieger Y; Ish-Shalom E; Olga M; Saragovi A; Shtainberg H; Lotem M; Baniyash M
    Clin Cancer Res; 2016 Dec; 22(23):5661-5672. PubMed ID: 27178742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review.
    Johnson DB; Peng C; Abramson RG; Ye F; Zhao S; Wolchok JD; Sosman JA; Carvajal RD; Ariyan CE
    Oncologist; 2015 Jun; 20(6):648-52. PubMed ID: 25964307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variations in cytotoxic T-lymphocyte antigen-4 and susceptibility to cervical cancer.
    Xiong YH; He L; Fei J
    Int Immunopharmacol; 2014 Jan; 18(1):71-6. PubMed ID: 24201079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with B-cell chronic lymphocytic leukemia in the Polish population.
    Suwalska K; Pawlak E; Karabon L; Tomkiewicz A; Dobosz T; Urbaniak-Kujda D; Kuliczkowski K; Wolowiec D; Jedynak A; Frydecka I
    Hum Immunol; 2008 Mar; 69(3):193-201. PubMed ID: 18396212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.